326 related articles for article (PubMed ID: 23833274)
21. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
Pettinelli P; Obregón AM; Videla LA
Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
[TBL] [Abstract][Full Text] [Related]
22. Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis.
Gaens KH; Niessen PM; Rensen SS; Buurman WA; Greve JW; Driessen A; Wolfs MG; Hofker MH; Bloemen JG; Dejong CH; Stehouwer CD; Schalkwijk CG
J Hepatol; 2012 Mar; 56(3):647-55. PubMed ID: 21907687
[TBL] [Abstract][Full Text] [Related]
23. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
[TBL] [Abstract][Full Text] [Related]
24. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
Musso G; Gambino R; Bo S; Uberti B; Biroli G; Pagano G; Cassader M
Diabetes Care; 2008 Mar; 31(3):562-8. PubMed ID: 18056890
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic fatty liver disease.
Angulo P
Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
[TBL] [Abstract][Full Text] [Related]
26. Non-alcoholic fatty liver disease and hepatitis C infection.
Bondini S; Younossi ZM
Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
[TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic steatohepatitis: a microbiota-driven disease.
Moschen AR; Kaser S; Tilg H
Trends Endocrinol Metab; 2013 Nov; 24(11):537-45. PubMed ID: 23827477
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
Schäffler A; Schölmerich J; Büchler C
Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
[TBL] [Abstract][Full Text] [Related]
29. The role of angiotensin II in nonalcoholic steatohepatitis.
Matthew Morris E; Fletcher JA; Thyfault JP; Rector RS
Mol Cell Endocrinol; 2013 Sep; 378(1-2):29-40. PubMed ID: 22579612
[TBL] [Abstract][Full Text] [Related]
30. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
[TBL] [Abstract][Full Text] [Related]
31. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model.
Aparicio-Vergara M; Hommelberg PP; Schreurs M; Gruben N; Stienstra R; Shiri-Sverdlov R; Kloosterhuis NJ; de Bruin A; van de Sluis B; Koonen DP; Hofker MH
Hepatology; 2013 Feb; 57(2):566-76. PubMed ID: 22941955
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?
Gruben N; Shiri-Sverdlov R; Koonen DP; Hofker MH
Biochim Biophys Acta; 2014 Nov; 1842(11):2329-2343. PubMed ID: 25128743
[TBL] [Abstract][Full Text] [Related]
34. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance.
Zheng H; Li S; Ma L; Cheng L; Deng C; Chen Z; Xie C; Xiang M; Jiang W; Chen L
Eur J Pharmacol; 2011 Jun; 659(2-3):244-51. PubMed ID: 21463618
[TBL] [Abstract][Full Text] [Related]
35. [Adipocitokines and nonalcoholic steatohepatitis].
Lăcătuşu C; Mihai B; Cijevschi-Prelipcean C; Mihai C; Graur M
Rev Med Chir Soc Med Nat Iasi; 2008; 112(4):882-9. PubMed ID: 20209757
[TBL] [Abstract][Full Text] [Related]
36. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease.
Cheung O; Sanyal AJ
Semin Liver Dis; 2008 Nov; 28(4):351-9. PubMed ID: 18956291
[TBL] [Abstract][Full Text] [Related]
37. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
Rafiq N; Younossi ZM
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
[TBL] [Abstract][Full Text] [Related]
38. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Choi SS; Diehl AM
Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
[TBL] [Abstract][Full Text] [Related]
39. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.
Xing LJ; Zhang L; Liu T; Hua YQ; Zheng PY; Ji G
Eur J Pharmacol; 2011 Oct; 668(3):467-71. PubMed ID: 21839075
[TBL] [Abstract][Full Text] [Related]
40. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
Schreuder TC; Marsman HA; Lenicek M; van Werven JR; Nederveen AJ; Jansen PL; Schaap FG
Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G440-5. PubMed ID: 20093562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
